Alk-Abello ASWBO:ALKB -0.12%65 Days Payable is 28.83 as of Mar. 2026, which is 7% above its 10-year median of 26.87. GuruFocus rates WBO:ALKB with a GF Score™ of 65/100 and a GF Value™ of €27.26 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 707 Biotechnology companies, Alk-Abello AS ranks worse than 85.29% on this metric.
The historical rank and industry rank for Alk-Abello AS's Days Payable or its related term are showing as below:
WBO:ALKB'
s Days Payable Range Over the Past 10 Years
Min: 19.34 Med: 26.87 Max: 38.56
Current: 24.99
During the past 13 years, Alk-Abello AS's highest Days Payable was 38.56. The lowest was 19.34. And the median was 26.87.
WBO:ALKB's Days Payable is ranked worse than 85.29% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs WBO:ALKB: 24.99
Alk-Abello AS's Days Payable
increased
from Mar. 2025 (27.23) to Mar. 2026 (28.83).
It may suggest that Alk-Abello ASdelayed paying its suppliers.
Alk-Abello AS Days Payable Related Terms
Alk-Abello AS Days Payable Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:ALKB vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Alk-Abello AS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Days Payable distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Alk-Abello AS's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS (WBO:ALKB) has a Days Payable of 28.83 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alk-Abello AS and its competitors. This is near median its historical median of 26.87. Over the past decade, Alk-Abello AS's Days Payable has ranged from 19.34 to 38.56. According to the industry distribution chart, Alk-Abello AS ranks #603 out of 707 companies in the Biotechnology industry, placing it in the top 85.3%.
Is Alk-Abello AS's Days Payable too high?
Alk-Abello AS's current Days Payable of 28.83 is near median its 10-year median of 26.87. Over the past 10 years, this metric has ranged from a low of 19.34 to a high of 38.56. The Biotechnology industry median Days Payable is 113.76. Alk-Abello AS's value of 28.83 is 74.7% below this industry median. Based on the distribution chart, Alk-Abello AS ranks #603 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alk-Abello AS has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #603 out of 707 companies for Days Payable. This places Alk-Abello AS in the lower half of its industry. The industry median Days Payable is 113.76. Alk-Abello AS's value of 28.83 is 74.7% below this benchmark. Historically, Alk-Abello AS's own Days Payable has ranged from 19.34 to 38.56 over the past decade. While the company's 10-year median is 26.87 vs. the industry median of 113.76, Alk-Abello AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current Days Payable of 28.83 is 74.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alk-Abello AS and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current Days Payable is 28.83, which is near median its own 10-year median of 26.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (WBO:ALKB) is currently considered Modestly Overvalued. The stock's GF Value™ is €27.26, compared to a current price of €34.22 — trading 25.5% above its estimated fair value. The current Days Payable is 28.83, which is near median its 10-year median of 26.87 and 74.7% below the Biotechnology industry median of 113.76. Alk-Abello AS's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Alk-Abello AS (WBO:ALKB), the current Days Payable is 28.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (WBO:ALKB) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of €34.22 is trading 25.5% above its estimated GF Value™ of €27.26.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for WBO:ALKB:
Days Payable: 28.83 (near median its 10-year median of 26.87)
GF Value™: €27.26 vs. price of €34.22 (25.5% above fair value)
Industry Position: 74.7% below the Biotechnology median (#603 of 707)
No single metric tells the full story. See the WBO:ALKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
65GF Score
Get the complete analysis for WBO:ALKB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ALKB has been successfully added to your 
